Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Table 6 Discounted base case model outcomes

	VR-CAP	R-CHOP	Difference^a
Deterministic results
QALYs	4.10	3.29	0.81
Progression-free survival from first-line treatment	2.70	1.54	1.16
Progressed from first-line treatment	0.14	0.10	0.03
Progression-free survival from second-line treatment	0.12	0.15	−0.03
Progressed from second-line treatment	1.15	1.50	−0.35
Costs	£45,842	£29,630	£16,212
First line therapy medication costs	£22,606	£8,041	£14,566
Administration of first line therapy	£5,817	£1,564	£4,253
Adverse events, transfusions & concomitant medication	£1,472	£1,105	£367
Disease management costs	£4,191	£4,676	−£486
Second line treatment (medication and administration)	£7,152	£9,423	−£2,271
Terminal care	£4,605	£4,821	−£217
Deterministic ICER (£/QALY gained)			£20,043
Probabilistic results
QALYs	4.09	3.28	0.81
Costs	£45,482	£29,285	£16,196
Probabilistic ICER (£/QALY gained)			£19,889

Abbreviations: ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone
^aSome differences due to rounding. First line therapy costs: medication costs of first line treatment; Administration costs: costs of administration of first-line therapies; Adverse events and concomitant medication costs: costs associated with adverse events (treatment of adverse events, concomitant medication and transfusions); Medical resource use; all costs for disease management, such as follow up visits and tests; Second line treatment costs; costs for medication and administration of the subsequent line of treatment; Terminal care costs: costs for end-of-life care
Total costs and QALYs, as well as the ICERs are presented in bold text

ISSN: 1471-2407